| First Author | de Thé H | Year | 2017 |
| Journal | Cancer Cell | Volume | 32 |
| Issue | 5 | Pages | 552-560 |
| PubMed ID | 29136503 | Mgi Jnum | J:249321 |
| Mgi Id | MGI:6093883 | Doi | 10.1016/j.ccell.2017.10.002 |
| Citation | de The H, et al. (2017) Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. Cancer Cell 32(5):552-560 |
| abstractText | Recent clinical trials have demonstrated that the immense majority of acute promyelocytic leukemia (APL) patients can be definitively cured by the combination of two targeted therapies: retinoic acid (RA) and arsenic. Mouse models have provided unexpected insights into the mechanisms involved. Restoration of PML nuclear bodies upon RA- and/or arsenic-initiated PML/RARA degradation is essential, while RA-triggered transcriptional activation is dispensable for APL eradication. Mutations of the arsenic-binding site of PML/RARA, but also PML, have been detected in therapy-resistant patients, demonstrating the key role of PML in APL cure. PML nuclear bodies are druggable and could be harnessed in other conditions. |
